康方生物-B(09926.HK)治療強直性脊柱炎藥物臨牀試驗完成受試者入組
康方生物-B(09926.HK)公佈,公司自主研發的創新藥Gumokimab(IL -17A單克隆抗體,研發代號:AK111)治療活動性強直性脊柱炎Ⅱ期臨牀試驗完成受試者入組。該臨牀試驗旨在評估Gumokimab治療活動性強直性脊柱炎受試者的療效與安全性。
強直性脊柱炎是累及中軸關節的慢性炎症性疾病,可導致患者脊柱畸形、功能喪失。
Gumokimab是公司自主研發的靶向IL -17A的新型自身免疫疾病治療藥物,擬用於治療銀屑病、強直性脊柱炎等疾病。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.